Translational Development Acquisition Corp.
TDAC
$10.45
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -36.36% | 160.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.36% | 160.42% | |||
| Operating Income | 36.36% | -160.42% | |||
| Income Before Tax | 9.45% | 18,638.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.45% | 18,638.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.45% | 18,638.75% | |||
| EBIT | 36.36% | -160.42% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 9.45% | 4,613.33% | |||
| Normalized Basic EPS | 9.46% | 4,800.00% | |||
| EPS Diluted | 9.45% | 4,613.33% | |||
| Normalized Diluted EPS | 9.46% | 4,800.00% | |||
| Average Basic Shares Outstanding | 0.00% | 304.20% | |||
| Average Diluted Shares Outstanding | 0.00% | 304.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||